Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer

Luis Barreras, Charles Vogel, Grace Koch, Stephen G. Marcus

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Nine patients with metastatic breast cancer received 30 × 106 I.U. of Interferon - Betaser (Betaseron) intravenously daily times five for two consecutive weeks followed by a two week rest period. Only one patient received more than one such cycle of Betaseron. The drug was well tolerated in eight of these patients. One patient, with liver metastases and liver dysfunction, developed hepatic decompensation during therapy. Toxicity consisted of anorexia, chills, fever, fatigue and nausea with an occasional patient having emesis. One patient developed severe thrombocytopenia, two, significant leukopenia and nine, mild elevations of serum transaminase. Two patients developed beta interferon binding antibodies but none developed neutralizing antibodies. No anti-tumor responses were seen and disease progression occurred rapidly during the four week cycle in eight of nine patients.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalInvestigational New Drugs
Volume6
Issue number3
DOIs
StatePublished - Sep 1 1988

Fingerprint

Interferons
Breast Neoplasms
Therapeutics
Chills
Interferon-beta
Liver
Leukopenia
Anorexia
Transaminases
Neutralizing Antibodies
Thrombocytopenia
Nausea
Vomiting
Fatigue
Disease Progression
Liver Diseases
Fever
Neoplasm Metastasis
Antibodies
Serum

Keywords

  • breast cancer
  • phase II beta interferon

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer. / Barreras, Luis; Vogel, Charles; Koch, Grace; Marcus, Stephen G.

In: Investigational New Drugs, Vol. 6, No. 3, 01.09.1988, p. 211-215.

Research output: Contribution to journalArticle

@article{c4da1ebecffb42e19ebd6f414ebee50e,
title = "Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer",
abstract = "Nine patients with metastatic breast cancer received 30 × 106 I.U. of Interferon - Betaser (Betaseron) intravenously daily times five for two consecutive weeks followed by a two week rest period. Only one patient received more than one such cycle of Betaseron. The drug was well tolerated in eight of these patients. One patient, with liver metastases and liver dysfunction, developed hepatic decompensation during therapy. Toxicity consisted of anorexia, chills, fever, fatigue and nausea with an occasional patient having emesis. One patient developed severe thrombocytopenia, two, significant leukopenia and nine, mild elevations of serum transaminase. Two patients developed beta interferon binding antibodies but none developed neutralizing antibodies. No anti-tumor responses were seen and disease progression occurred rapidly during the four week cycle in eight of nine patients.",
keywords = "breast cancer, phase II beta interferon",
author = "Luis Barreras and Charles Vogel and Grace Koch and Marcus, {Stephen G.}",
year = "1988",
month = "9",
day = "1",
doi = "10.1007/BF00175400",
language = "English",
volume = "6",
pages = "211--215",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer

AU - Barreras, Luis

AU - Vogel, Charles

AU - Koch, Grace

AU - Marcus, Stephen G.

PY - 1988/9/1

Y1 - 1988/9/1

N2 - Nine patients with metastatic breast cancer received 30 × 106 I.U. of Interferon - Betaser (Betaseron) intravenously daily times five for two consecutive weeks followed by a two week rest period. Only one patient received more than one such cycle of Betaseron. The drug was well tolerated in eight of these patients. One patient, with liver metastases and liver dysfunction, developed hepatic decompensation during therapy. Toxicity consisted of anorexia, chills, fever, fatigue and nausea with an occasional patient having emesis. One patient developed severe thrombocytopenia, two, significant leukopenia and nine, mild elevations of serum transaminase. Two patients developed beta interferon binding antibodies but none developed neutralizing antibodies. No anti-tumor responses were seen and disease progression occurred rapidly during the four week cycle in eight of nine patients.

AB - Nine patients with metastatic breast cancer received 30 × 106 I.U. of Interferon - Betaser (Betaseron) intravenously daily times five for two consecutive weeks followed by a two week rest period. Only one patient received more than one such cycle of Betaseron. The drug was well tolerated in eight of these patients. One patient, with liver metastases and liver dysfunction, developed hepatic decompensation during therapy. Toxicity consisted of anorexia, chills, fever, fatigue and nausea with an occasional patient having emesis. One patient developed severe thrombocytopenia, two, significant leukopenia and nine, mild elevations of serum transaminase. Two patients developed beta interferon binding antibodies but none developed neutralizing antibodies. No anti-tumor responses were seen and disease progression occurred rapidly during the four week cycle in eight of nine patients.

KW - breast cancer

KW - phase II beta interferon

UR - http://www.scopus.com/inward/record.url?scp=0023770994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023770994&partnerID=8YFLogxK

U2 - 10.1007/BF00175400

DO - 10.1007/BF00175400

M3 - Article

C2 - 3192387

AN - SCOPUS:0023770994

VL - 6

SP - 211

EP - 215

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -